SCHEMBL12690199

SCHEMBL12690199

O=C1Nc2ncccc2O/C1=C\c1cccnc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK17B O94768 1/20 0.58
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.47
GSK3B P49841 1/20 0.47
GAA P10253 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MAPT P10636 7/20 0.45
HTT P42858 3/20 0.45
MAPK1 P28482 1/20 0.45
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
MAOB P27338 1/20 0.42
TDP1 Q9NUW8 2/20 0.42
HPGD P15428 1/20 0.42
DAPK3 O43293 1/20 0.41
RAB9A P51151 2/20 0.41
MITF O75030 1/20 0.41
LMNA P02545 1/20 0.41
ATM Q13315 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6015921 0.89 MEN1 (0.62) STK17BMEN1KMT2ASMN1; SMN2L3MBTL1
SCHEMBL6015927 0.89 MEN1 (0.62) STK17BMEN1KMT2ASMN1; SMN2L3MBTL1
SCHEMBL12690403 0.82 MEN1 (0.44) STK17BMEN1KMT2AMAPTTDP1
SCHEMBL12690400 0.81 MEN1 (0.43) STK17BMEN1KMT2ASMN1; SMN2GAA
SCHEMBL12537609 0.80 APP (0.61) MEN1KMT2ASMN1; SMN2MAPTMAPK1
SCHEMBL12537683 0.80 RAF1 (0.44) MEN1KMT2AMAPTHTTMAPK1
SCHEMBL12537680 0.80 RAF1 (0.44) MEN1KMT2AMAPTHTTMAPK1
SCHEMBL12537677 0.80 RAF1 (0.44) MEN1KMT2AMAPTHTTMAPK1
SCHEMBL12537612 0.80 APP (0.61) MEN1KMT2ASMN1; SMN2MAPTMAPK1
SCHEMBL12537613 0.80 APP (0.61) MEN1KMT2ASMN1; SMN2MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9567305-B2 Quinoxaline compounds and derivatives SOUTHERN METHODIST UNIVERSITY (US) 2017-02-14 US disclosed
US-9567305-B2 Quinoxaline compounds and derivatives SOUTHERN METHODIST UNIVERSITY (US) 2017-02-14 US disclosed
US-20170008907-A1 Compounds and Derivatives of 2H-Pyrido (3,2-b)(1, 4) Oxazin 3)4H)-Ones as raf Kinase and LRRK2 Inhibitors NATIONAL INSTITUTES OF HEALTH 2017-01-12 US disclosed
US-20170008907-A1 Compounds and Derivatives of 2H-Pyrido (3,2-b)(1, 4) Oxazin 3)4H)-Ones as raf Kinase and LRRK2 Inhibitors NATIONAL INSTITUTES OF HEALTH 2017-01-12 US disclosed
US-9493452-B2 Compounds and derivatives of 2H-pyrido (3,2-b)(1, 4) oxazin 3)4H)-ones as raf kinase and LRRK2 inhibitors SOUTHERN METHODIST UNIVERSITY (US) 2016-11-15 US disclosed
US-9493452-B2 Compounds and derivatives of 2H-pyrido (3,2-b)(1, 4) oxazin 3)4H)-ones as raf kinase and LRRK2 inhibitors SOUTHERN METHODIST UNIVERSITY (US) 2016-11-15 US disclosed
US-20140135494-A1 Quinoxaline Compounds and Derivatives SOUTHERN METHODIST UNIVERSITY (US) 2014-05-15 US disclosed
US-20140135494-A1 Quinoxaline Compounds and Derivatives SOUTHERN METHODIST UNIVERSITY (US) 2014-05-15 US disclosed
US-8669363-B2 Quinoxaline compounds and derivatives SOUTHERN METHODIST UNIVERSITY (US) 2014-03-11 US disclosed
US-8669363-B2 Quinoxaline compounds and derivatives SOUTHERN METHODIST UNIVERSITY (US) 2014-03-11 US disclosed
US-20120245347-A1 Compounds and Derivatives of 2H-Pyrido (3,2-b)(1, 4) Oxazin 3)4H)-Ones as raf Kinase and LRRK2 Inhibitors SOUTHERN METHODIST UNIVERSITY (US) 2012-09-27 US disclosed
US-20120245352-A1 Quinoxaline Compounds and Derivatives SOUTHERN METHODIST UNIVERSITY (US) 2012-09-27 US disclosed
US-20120245347-A1 Compounds and Derivatives of 2H-Pyrido (3,2-b)(1, 4) Oxazin 3)4H)-Ones as raf Kinase and LRRK2 Inhibitors SOUTHERN METHODIST UNIVERSITY (US) 2012-09-27 US disclosed
US-20120245352-A1 Quinoxaline Compounds and Derivatives SOUTHERN METHODIST UNIVERSITY (US) 2012-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120245347-A1 Compounds and Derivatives of 2H-Pyrido (3,2-b)(1, 4) Oxazin 3)4H)-Ones as raf Kinase and LRRK2 Inhibitors LRRK2, BRAF, RAF1 STK17B 77/4885MEN1 2436/4885KMT2A 1874/4885
US-20170008907-A1 Compounds and Derivatives of 2H-Pyrido (3,2-b)(1, 4) Oxazin 3)4H)-Ones as raf Kinase and LRRK2 Inhibitors LRRK2, BRAF, RAF1 STK17B 77/4885MEN1 2436/4885KMT2A 1874/4885
US-20140135494-A1 Quinoxaline Compounds and Derivatives CYP3A5, PDXK, QDPR STK17B 1252/4885MEN1 1575/4885KMT2A 2666/4885
US-20120245352-A1 Quinoxaline Compounds and Derivatives CYP3A5, PDXK, QDPR STK17B 1252/4885MEN1 1575/4885KMT2A 2666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.